Skip to main content
MBI logo

MBI — Investor Relations & Filings

Ticker · 1783 ISIN · TW0001783009 TW Manufacturing
Open in API
Filings indexed 1,692 across all filing types
Latest filing 2024-12-13 Board/Management Inform…
Country TW Taiwan
Listing TW 1783

About MBI

www.mbi.com.tw

Maxigen Biotech Inc. (MBI) is a medical device manufacturer specializing in the research, development, and production of biopolymer-based solutions, primarily focusing on collagen matrix and hyaluronic acid technologies. The company provides a comprehensive range of medical devices across multiple clinical disciplines, including orthopedics, aesthetics, ophthalmology, and wound care. Key products include hyaluronic acid intra-articular injections, dermal fillers, ophthalmic viscoelastics, collagen wound dressings, dental membranes, and synthetic bone grafts. In addition to its proprietary brands, MBI offers global OEM/ODM and customization services. The company adheres to international quality standards, holding certifications such as CE, FDA, NMPA, and MDSAP. MBI leverages its expertise in biopolymer science to deliver innovative medical and skincare products to international markets.

Recent filings

Filing Released Lang Actions
公告本公司獨立董事辭任
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the resignation of an independent director from the company. It includes details such as the resignation date, the name of the director, and the impact on the board composition. There is no financial data, no mention of financial results, reports, or filings related to earnings, audits, or capital changes. The content clearly relates to changes in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming the classification.
2024-12-13 Chinese
113年11月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company, 和康生, providing details about fund lending balances and endorsement guarantees for the current and previous months. It contains tabulated financial data but is very short (609 characters) and does not include comprehensive financial statements or analysis. It appears to be a regulatory disclosure related to financial guarantees and lending, typical of a regulatory filing rather than a full report or announcement. There is no indication of it being an annual report, interim report, earnings release, or any other specific report type. Therefore, it fits best under Regulatory Filings (RNS).
2024-12-09 Chinese
113年11月營業收入
Regulatory Filings Classification · 90% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 和康生, with data presented in a tabular format. It includes percentage changes compared to the previous year and explanatory notes about accounting standards and reporting practices. The document length is short (766 characters), and it does not contain detailed financial statements or comprehensive analysis. It appears to be a regulatory disclosure or a brief financial summary rather than a full financial report. There is no indication that this is an annual or interim report, audit report, or earnings release. The document is more consistent with a general regulatory filing or a financial summary disclosure. Given the short length and nature of the content, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-12-09 Chinese
公告本公司股務代理機構「元大證券股份有限公司股務代 理部」變更營業處所事宜
Regulatory Filings Classification · 95% confidence The document is a short announcement (878 characters) about the change of business location of the company's stock affairs agency. It provides details such as the new address and contact information for shareholders to handle stock-related matters. There is no financial data, no report attached or referenced, and no mention of financial results or management changes. This is a regulatory announcement related to shareholder services and stock affairs, fitting best under Regulatory Filings (RNS) as it does not fit other specific categories.
2024-12-05 Chinese
113年11月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in shareholdings by insiders, including directors, chairpersons, general managers, and other key personnel. It includes data on shares held, increases, decreases, and trust shares. The content is focused on insider share transactions and holdings, which is typical of a Director's Dealing report. There is no indication of financial statements, earnings data, or meeting results. The document length is substantial and contains actual data, not just an announcement or certification. Therefore, the document is best classified as a Director's Dealing report.
2024-12-04 Chinese
113年11月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders, including directors, independent directors, general manager, and other key personnel. It lists their share counts, pledged shares, and related information. The content focuses on insider shareholdings and changes, not on financial results, management changes, or meeting materials. There is no indication of a report publication or announcement, nor is there any financial statement or earnings data. The document is a notification of insider shareholdings and related disclosures, which aligns with the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 3029 characters, which is relatively short but contains detailed insider shareholding data, not just an announcement. Therefore, the best fitting classification is DIRS with high confidence.
2024-12-04 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.